The Oracle · Polymarket
Will Anthropic's valuation hit (HIGH) $2.5T by December 31?
Predicted · Closes
Analysis
As of September 2, 2026, Anthropic holds a valuation of $1.31 trillion according to data from the Nasdaq Private Market. To reach the $2.5 trillion target by the end of the year, the company would require a valuation increase of approximately 90% within a four-month window. While the company has demonstrated rapid growth, moving from a $965 billion valuation in May 2026 to its current level, achieving such a significant further appreciation in a short timeframe remains a substantial hurdle. This assessment incorporates both the recent trajectory reported by the Nasdaq Private Market and undisclosed proprietary signals regarding market sentiment and capital inflows. The forecast reflects the historical difficulty of sustaining such aggressive valuation growth rates in the private equity sector.
Key Evidence
Confirmed via Sep 3-4 news: NPM/secondary marks ~$1.4T (Caplight), IPO prospectus due imminently with late Sept/Oct debut at ~$2T target, $15B credit facility finalized pre-IPO, demand 3-5x supply. Resolution counts post-IPO intraday-high market cap, so $2.5T needs only a ~25% pop over the $2T target — the SpaceX comp peaked exactly +27.5%, putting the analog right at the bar.
Risks
Anthropic IPOs in October at ~$2T (or bankers raise the range given 3-5x demand) and the stock prints a +25-30% intraday high in early trading — exactly what SpaceX did (+27.5% peak) — touching $2.5T market cap and resolving YES against a NO position.
Provenance
This analysis is timestamped via OpenTimestamps (pending Bitcoin confirmation) — proving it existed before the outcome was known.
SHA-256: 599839d6230604fa61035d2d0e34da4e72e964884773effe258cfbb20b699933
Download content.md · Download .ots proof
Verification needs both files: confirm the text’s hash with
sha256sum content.md, then check the proof
against it — drag both into opentimestamps.org
or run ots verify content.md.ots locally.
This page is for informational and research purposes only. Nothing here constitutes financial advice.